Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

L7RSL8 (L7RSL8_HUMAN) Homo sapiens (Human)

small monomeric GTPase UniProtKBInterProInteractive Modelling

189 aa; Sequence (Fasta) ; 34 identical sequences

Available Structures

323 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
NMR data-driven model of GTPase KRas-GMPPNP tethered to a nanodisc (E3 state) Heteromer
P01116; P02647;
1-186
64×PCW; 16×17F;GNP;MG;
Assess
NMR data-driven model of KRas-GMPPNP:RBD-CRD complex tethered to a nanodisc (state B) Heteromer
P01116; P02647; P04049;
1-186
64×PCW; 16×17F;GNP;MG;ZN;
Assess
NMR data-driven model of GTPase KRas-GMPPNP:Cmpd2 complex tethered to a nanodisc Heteromer
P01116; P02647;
1-186
64×PCW; 16×17F;GNP;MG;EWS;
Assess
NMR data-driven model of KRas-GMPPNP:RBD-CRD complex tethered to a nanodisc (state A) Heteromer
P01116; P02647; P04049;
1-186
64×PCW; 16×17F;GNP;MG;ZN;
Assess
NMR data-driven model of GTPase KRas-GNP:ARafRBD complex tethered to a lipid-bilayer nanodisc Heteromer
P01116; P02647; P10398;
1-186
64×PCW; 16×17F;GNP;MG;
Assess
NMR data-driven model of GTPase KRas-GDP tethered to a lipid-bilayer nanodisc Heteromer
P01116; P02647;
1-186
64×PCW; 16×17F;GDP;MG;
Assess
NMR data-driven model of GTPase KRas-GNP tethered to a lipid-bilayer nanodisc Heteromer
P01116; P02647;
1-186
64×PCW; 16×17F;GNP;MG;
Assess
NMR data-driven model of GTPase KRas-GMPPNP:Cmpd2 complex tethered to a nanodisc Heteromer
P01116; P02647;
1-186
64×PCW; 16×17F;GNP;MG;EWS;
Assess
Crystal structure of farnesylated and methylated kras4b in complex with PDE-delta (crystal form II … Heteromer
O43924; P01116;
2-186
FAR;GDP;EDO;
Assess
Crystal structure of full-length farnesylated and methylated KRAS4b in complex with PDE-delta (crys… Heteromer
O43924; P01116;
2-186
FAR;GDP;EDO;
Assess
Crystal structure of the high affinity KRas mutant PDE6D complex Heteromer
O43924; P01116;
2-186
GDP;FAR;SO4;EDO;
Assess
NMR-driven structure of the KRAS4B-G12D "alpha-beta" dimer on a lipid bilayer nanodisc Heteromer
P01116; P02647;
2-185
GSP;MG; 128×7Q9; 32×17F;
Assess
NMR-driven structure of the KRAS4B-G12D "alpha-alpha" dimer on a lipid bilayer nanodisc Heteromer
P01116; P02647;
2-185
GSP;MG; 128×7Q9; 32×17F;
Assess
NMR-driven structure of KRAS4B-GTP homodimer on a lipid bilayer nanodisc Heteromer
P01116; P02647;
2-185
64×PCW; 16×17F;GSP;MG;
Assess
NMR-driven structure of KRAS4B-GDP homodimer on a lipid bilayer nanodisc Heteromer
P01116; P02647;
2-185
64×PCW; 16×17F;GDP;MG;
Assess
Crystal structure of KRAS4a (GMPPNP) in complex with RAF1 (RBD) Heteromer
P01116; P04049;
1-170
MG;GNP;
Assess
KRAS full-length G12V in complex with RGL1 Ras association domain Heteromer
P01116; Q9NZL6;
1-170
MG;GSP;PO4;
Assess
KRAS full length wild-type in complex with RGL1 Ras association domain Heteromer
P01116; Q9NZL6;
1-170
MG;GSP;
Assess
Crystal Structure of KRAS4a (GMPPNP) in complex with RAF1 (RBD-CRD) Heteromer
P01116; P04049;
1-170
GNP;MG;ZN;
Assess
Crystal structure of human K-Ras G12D Mutant in complex with GDP and Cyclic Inhibitory Peptide Heteromer
P01116;
1-169
GDP;EDO;
Assess
Tricomplex of RMC-7977, KRAS G12C, and CypA Heteromer
P01116; P62937;
1-169
GNP;MG;ZNI;
Assess
Tricomplex of Compound-1, KRAS G12C, and CypA Heteromer
P01116; P62937;
1-169
GNP;MG;YV6;
Assess
Tricomplex of RMC-7977, KRAS G12A, and CypA Heteromer
P01116; P62937;
1-169
GNP;MG;ZNI;
Assess
Human K-Ras G12D (GDP-bound) in complex with cyclic peptide inhibitor LUNA18 and KA30L Fab Heteromer
P01116;
2-170
GDP;MG;
Assess
Tricomplex of RMC-4998, KRAS G12C, and CypA Heteromer
P01116; P62937;
1-169
GNP;MG;CL;YV2;
Assess
Tricomplex of RMC-7977, KRAS G12R, and CypA Heteromer
P01116; P62937;
1-169
GNP;MG;ZNI;
Assess
Tricomplex of RMC-7977, KRAS WT, and CypA Heteromer
P01116; P62937;
1-169
GNP;MG;ZNI;
Assess
Crystal structure of G13D-KRAS (GMPPNP-bound) in complex with GAP-related domain (GRD) of neurofibr… Heteromer
P01116; P21359;
1-169
GNP;MG;CL;MES;
Assess
Crystal structure of Kas G12C in complex with 2H11 CLAMP Heteromer
P01116;
1-169
GDP;MG;CAC;EDO;
Assess
RAS GUANINE EXCHANGE FACTOR SOS1 (REM-CDC25) IN COMPLEX WITH KRAS(G12C) AND FRAGMENT SCREENING HIT … Heteromer
P01116; Q07889;
1-169
GOL;BPW;
Assess
Ras guanine exchange factor SOS1 (Rem-cdc25) in complex with KRAS(G12C) and fragment screening hit … Heteromer
P01116; Q07889;
1-169
GOL;BQ2;DMS;
Assess
Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with KRAS(G12C) and fragment scr… Heteromer
P01116; Q07889;
1-169
GOL;BQ5;
Assess
Ras guanine exchange factor SOS1 (Rem-cdc25) in complex with KRAS(G12C) Heteromer
P01116; Q07889;
1-169
GOL;
Assess
Crystal structure of wild-type KRAS (GMPPNP-bound) in complex with GAP-related domain (GRD) of neur… Heteromer
P01116; P21359;
1-169
GOL;GNP;MG;IMD;CL;
Assess
Tricomplex of RMC-7977, KRAS G12S, and CypA Heteromer
P01116; P62937;
1-168
GNP;MG;ZNI;
Assess
Crystal Structure of KRAS-G13D (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine… Heteromer
P01116; P04049;
1-168
GNP;MG;ZN;GOL;CL;
Assess
RAS GUANINE EXCHANGE FACTOR SOS1 (REM-CDC25) IN COMPLEX WITH KRAS(G12C) AND FRAGMENT SCREENING HIT … Heteromer
P01116; Q07889;
1-168
GOL;BOQ;
Assess
Monobody 12D5 bound to KRAS(G12D) Heteromer
P01116;
1-168
MG;GDP;GLC;
Assess
Crystal Structure of wild-type KRAS (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cys… Heteromer
P01116; P04049;
1-168
GNP;MG;CL;GOL;IPA;ZN;
Assess
Crystal structure of Q61L KRAS(GMPPNP)-NF1(GRD)-SPRED1(EVH1) complex Heteromer
P01116; P21359; Q7Z699;
1-168
FMT;GNP;MG;ZN;
Assess
Crystal Structure of KRAS-Q61R (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine… Heteromer
P01116; P04049;
1-168
GNP;MG;ZN;GOL;
Assess
Crystal structure of KRAS(GMPPNP)-NF1(GRD)-SPRED1 complex Heteromer
P01116; P21359; Q7Z699;
1-168
FMT;GNP;MG;ZN;
Assess
KRAS G13C complex with GDP imaged on a cryo-EM imaging scaffold Heteromer
P01116;
1-168
GDP;MG;
Assess
Structure of a ternary KRas(G13D)-SOS complex Heteromer
P01116; Q07889;
1-168
GNP;MG;
Assess
KRAS G12C complex with GDP and AMG 510 imaged on a cryo-EM imaging scaffold Heteromer
P01116;
1-168
MG;GDP;MOV;
Assess
Crystal Structure of wild-type KRAS4b (GMPPNP-bound) in complex with RAS-binding domain (RBD) of RA… Heteromer
P01116; P04049;
1-167
MG;GNP;CL;EDO;MPD;
Assess
Tricomplex of RMC-7977, KRAS G12V, and CypA Heteromer
P01116; P62937;
1-167
GNP;MG;ZNI;
Assess
Affimer K69 - KRAS protein complex Heteromer
P01116;
1-167
GDP;MG;
Assess
Tricomplex of RMC-7977, KRAS G12D, and CypA Heteromer
P01116; P62937;
1-167
GNP;MG;ZNI;
Assess
KRas G12C in complex with G-2897 Heteromer
P01116;
1-167
Z07;GDP;MG;ACT;CAD;P15;EDO;DMS;
Assess
Crystal Structure of KRAS4b-G13D (GMPPNP-bound) in complex with RAS-binding domain (RBD) of RAF1/CR… Heteromer
P01116; P04049;
1-167
GNP;MG;
Assess
KRAS G12V and H-REV107 peptide complex Heteromer
P01116; P53816;
1-167
GDP;MG;
Assess
Crystal Structure of KRAS4b (GMPPNP-bound) in complex with the RBD-PH domains of SIN1 Heteromer
P01116; Q9BPZ7;
1-167
MG;GNP;
Assess
Monobody 12D1 bound to KRAS(G12D) Heteromer
P01116;
1-167
GDP;MG;NA;
Assess
Heterotetramer of K-Ras4B(G12V) and Rgl2(RBD) Heteromer
O15211; P01116;
1-167
MG;GNP;
Assess
Cryo-EM structure of a RAS/RAF complex (state 2) Heteromer
P01116; P15056; Q02750; V9P4T4;
1-167
AGS;ZN;MG;LCJ;GNP;
Assess
Cryo-EM structure of a RAS/RAF complex (state 1) Heteromer
P01116; P15056; Q02750; V9P4T4;
1-167
AGS;ZN;MG;LCJ;GNP;
Assess
Crystal Structure of KRas4A(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1 Heteromer
P01116; Q9BPZ7;
1-166
MG;GNP;
Assess
Human KRAS in complex with darpin K19 Heteromer
P01116;
1-166
SO4;
Assess
KRas G12V, bound to GppNHp and miniprotein 225-15a/b Heteromer
P01116;
1-166
GNP;MG;PG4;SO4;
Assess
KRasG12C ligand complex Heteromer
A0A1S2ZE25; P01116;
1-166
MG;GDP;MKW;
Assess
Affimer K6 - KRAS protein complex Heteromer
P01116;
1-166
GDP;MG;
Assess
Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP Heteromer
P01116;
2-167
MKZ;GDP;MG;GOL;EDO;SO4;
Assess
Affimer K3 - KRAS protein complex Heteromer
P01116;
2-167
GDP;MG;
Assess
KRas G12V, bound to GDP and miniprotein 225-11(A30R) Heteromer
P01116;
1-166
GDP;MG;CA;
Assess
K-RasG12D(GNP)/R11.1.6 complex Heteromer
P01116;
1-166
GNP;MG;CL;CA;CD;
Assess
Human KRAS in complex with darpin K13 Heteromer
P01116;
1-166
GDP;SO4;
Assess
Wild-type K-Ras(GNP)/R11.1.6 complex Heteromer
P01116;
1-166
GNP;CA;CD;CL;MG;CO;
Assess
Crystal Structure of compound 4 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB Heteromer
P01116; P40337; Q15369; Q15370;
3-168
X53;GDP;MG;
Assess
Crystal Structure of KRAS4b-Q61R (GMPPNP-bound) in complex with the RAS-binding domain (RBD) of SIN1 Heteromer
P01116; Q9BPZ7;
1-166
GNP;MG;
Assess
KRas G12V/D38P, bound to GppNHp and miniprotein 225-11 Heteromer
P01116;
2-166
GNP;CA;MG;
Assess
KRas G12V, bound to GDP and miniprotein 225-11 Heteromer
P01116;
2-166
MG;GDP;CA;
Assess
Crystal structure of human RAS in complex with darpin K27 Heteromer
P01116;
1-165
GDP;MG;
Assess
Human KRAS in complex with darpin K27 Heteromer
P01116;
1-165
GDP;MG;
Assess
KRAS G12C complex with GDP imaged on a cryo-EM imaging scaffold Heteromer
P01116;
1-165
GDP;MG;
Assess
KRAS G12V complex with GDP imaged on a cryo-EM imaging scaffold Heteromer
P01116;
1-165
GDP;MG;
Assess
KRas G12V, bound to GppNHp and miniprotein 225-11(A30R) Heteromer
P01116;
1-164
GNP;MG;SO4;
Assess
Crystal structure of human RAS in complex with darpin K55 Heteromer
P01116;
1-164
MG;GSP;SO4;
Assess
Human KRAS in complex with darpin K27 Heteromer
P01116;
1-164
MG;GSP;SO4;
Assess
Crystal Structure of compound 3 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB Heteromer
P01116; P40337; Q15369; Q15370;
3-166
GDP;X4R;MG;
Assess
Crystal Structure of ligand ACBI3 in complex with KRAS G12D C118S GDP and pVHL:ElonginC:ElonginB co… Heteromer
P01116; P40337; Q15369; Q15370;
3-166
WYL;GDP;MG;
Assess
PROTAC-mediated complex of KRAS with VHL/Elongin-B/Elongin-C/Cullin-2/Rbx1 Heteromer
P01116; P40337; P62877; Q13617; Q15369; Q15370;
1-164
ZN;GDP;WYL;
Assess
Structure of HLA-A2:01 with peptide MM96 Heteromer
A0A140T913; P01116; P61769;
5-14
GOL;SO4;NA;
Assess
Crystal structure of HLA-C05 in complex with a tumor mut10m peptide Heteromer
P01116; P10321; P61769;
10-19
Assess
Crystal structure of HLA-C08 in complex with a tumor mut10m peptide Heteromer
C1K0Y1; P01116; P61769;
10-19
Assess
Structure of KRAS WT(7-16)-HLA-A*03:01 Heteromer
P01116; P04439; P61769;
7-16
13×SO4;PEG;
Assess
Structure of KRAS G12V/HLA-A*03:01 in complex with antibody fragment V2 Heteromer
P01116; P04439; P61769;
7-16
Assess
Structure of HLA-A2:01 with peptide MM90 Heteromer
A0A140T913; P01116; P61769;
6-14
GOL;NA;
Assess
Crystal structure of HLA-C08 in complex with a tumor mut9m peptide Heteromer
C1K0Y1; P01116; P61769;
10-18
Assess
Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVGAGGVGK) Heteromer
P01116; P61769; U5YJJ6;
8-16
Assess
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK) Heteromer
P01116; P61769; U5YJJ6;
8-16
Assess
Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVGAVGVGK) Heteromer
P01116; P61769; U5YJJ6;
8-16
Assess
Structure of HLA-A2:01 with peptide MM92 Heteromer
A0A140T913; P01116; P61769;
5-12
GOL;NA;SO4;
Assess
Structure of HLA-A2:01 with peptide MM91 Heteromer
A0A140T913; P01116; P61769;
7-14
GOL;NA;
Assess
CO-CRYSTAL STRUCTURE OF RAT PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH A K-RAS4B PEPTIDE SUBSTRATE … Heteromer
P01116; Q02293; Q04631;
185-189
ZN;ACT;FII;
Assess
PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH A FARNESYLATED K-RAS4B PEPTIDE PRODUCT Heteromer
P01116; Q02293; Q04631;
185-189
ZN;ACY;FAR;
Assess
PROTEIN FARNESYLTRANSFERASE COMPLEXED WITH FARNESYLATED K-RAS4B PEPTIDE PRODUCT AND FARNESYL DIPHOS… Heteromer
P01116; Q02293; Q04631;
185-189
ZN;FPP;ACY;FAR;
Assess
Protein Geranylgeranyltransferase type-I Complexed with a GGPP Analog and a KKKSKTKCVIL Peptide Heteromer
P01116; P53610; Q04631;
185-189
ZN;MGM;
Assess
Protein Geranylgeranyltransferase type-I Complexed with a Geranylgeranylated KKKSKTKCVIL Peptide Pr… Heteromer
P01116; P53610; Q04631;
185-189
MES;ZN;SO4;GER;
Assess
Zinc-depleted FTase complexed with K-RAS4B peptide substrate and FPP analog. Heteromer
P01116; Q02293; Q04631;
185-189
ACT;FII;
Assess
Protein Geranylgeranyltransferase type-I Complexed with GGPP and a Geranylgeranylated KKKSKTKCVIL P… Heteromer
P01116; P53610; Q04631;
186-189
ZN;CL;GRG;GER;
Assess
Protein Geranylgeranyltransferase type-I Complexed with Geranylgeranyl Diphosphate Heteromer
P01116; P53610; Q04631;
186-189
ZN;CL;GRG;GER;
Assess
Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method.homo-6-mer1-169
GNP;9RK;PEG;MG;CIT;
Assess
Antibody derived (Abd-4) small molecule binding to KRAS.homo-6-mer1-169
MG;GNP;D2Z;
Assess
KRAS-169 Q61H GPPNHPhomo-6-mer1-169
GNP;MG;CIT;
Assess
Antibody derived (Abd-8) small molecule binding to KRAS.homo-6-mer1-169
MG;GNP;CVK;
Assess
Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method.homo-6-mer1-168
GNP;9R5;PEG;MG;DMS;
Assess
KRAS G12V and peptide complexhomo-6-mer1-167
MG;GDP;
Assess
Crystal structure of KRAS-G75A mutant, GDP-boundhomo-4-mer1-168
GDP;MG;
Assess
Crystal Structure of small molecule vinylsulfonamide 9 covalently bound to K-Ras G12Chomo-3-mer1-169
SO4;GDP;21F;
Assess
Crystal Structure of small molecule vinylsulfonamide 8 covalently bound to K-Ras G12Chomo-3-mer1-167
GDP;21C;
Assess
CRYSTAL STRUCTURE OF INACTIVE KRAS G12D (GDP) IN COMPLEX WITH THE SOAKED DIMERIC INHIBITOR BI-5747homo-3-mer1-167
GDP;MG;R6W;
Assess
KRAS4B A146V 1-185 bound to GDPhomo-2-mer3-172
GDP;
Assess
Second-site screening of K-Ras in the presence of covalently attached first-site ligandshomo-2-mer1-169
GDP;MG;2XR;
Assess
Crystal Structure of small molecule disulfide 6 bound to K-Ras G12Chomo-2-mer1-168
CA;20G;GDP;
Assess
Crystal structure of KRAS A146T-GDP demonstrating open switch 1 conformationhomo-2-mer2-169
GDP;
Assess
Crystal Structure of small molecule disulfide 4 covalently bound to K-Ras G12Chomo-2-mer1-168
CA;20H;GDP;
Assess
CRYSTAL STRUCTURE OF CRYSTAL FORM 2 OF AN ACTIVE KRAS G12D (GPPCP) DIMER IN COMPLEX WITH BI-5747homo-2-mer1-168
MG;GCP;R6W;
Assess
Crystal structure of KRAS-G12D/G75A mutant, GDP-boundhomo-2-mer1-168
GDP;MG;NA;CL;
Assess
Crystal Structure of KRAS-G12D in Complex with Natural Product-Like Compound 9bhomo-2-mer1-167
GCP;MG;JJQ;
Assess
Crystal Structure of KRAS-G12D in complex with GMP-PCP and compound 15Rhomo-2-mer1-167
GCP;MG;JJN;
Assess
CRYSTAL STRUCTURE OF AN ACTIVE KRAS G12D (GPPCP) DIMER IN COMPLEX WITH BI-5747homo-2-mer1-167
MG;GCP;R6W;
Assess
Crystal Structure of KRAS-G12D in Complex with Natural Product-Like Compound 15homo-2-mer1-167
GCP;MG;EDO;JJN;
Assess
Crystal structure of small molecule aziridine 3 covalently bound to K-Ras G12Chomo-2-mer2-168
GDP;CA;8YA;GOL;
Assess
CRYSTAL STRUCTURE OF ACTIVE KRAS G12D (GPPCP) IN COMPLEX WITH THE SOAKED DIMERIC INHIBITOR BI-5747homo-2-mer1-167
R6W;GCP;MG;
Assess
Crystal Structure of K-Ras G12C (cysteine-light), GDP-boundhomo-2-mer2-167
MG;GDP;
Assess
Solution structures of full-length K-RAS bound to GDPmonomer1-189
Assess
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchang…monomer2-181
GDP;MG;BZI;
Assess
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchang…monomer2-181
GSP;MG;BEN;GOL;
Assess
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchang…monomer2-181
GCP;MG;EDO;
Assess
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchang…monomer2-181
9LI;GCP;MG;GOL;EDO;DMS;ACT;
Assess
KRAS4b K117N 1-185 bound to GNP-Mg2+monomer1-176
GNP;MG;
Assess
KRAS4b WT 1-185 bound to GDP-Mg2+monomer1-172
MG;GDP;GOL;
Assess
Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method.monomer2-173
MG;GNP;9R5;GOL;PEG;
Assess
Crystal structure analysis of human KRAS mutantmonomer2-173
GDP;
Assess
KRAS full length wild-type GPPNHPmonomer2-173
MG;GNP;GOL;
Assess
KRAS full length G12D GPPNHPmonomer2-173
MG;GNP;
Assess
KRAS4b A146T 1-185 bound to GDPmonomer2-172
GDP;
Assess
Crystal Structure of WT KRAS4a with bound GDP and Mg ionmonomer1-171
GDP;MG;
Assess
Human K-Ras G12D (GDP-bound) in complex with cyclic peptide inhibitor AP8784monomer2-171
GDP;MG;IOD;
Assess
Crystal Structure of a GDP-bound G12R Oncogenic Mutant of Human GTPase KRasmonomer1-169
GDP;MG;
Assess
KRAS-G12D in complex with BI-2865monomer1-169
GDP;MG;EDO;OFU;
Assess
Crystal structure of human KRAS at 1.12 Amonomer1-169
MG;GDP;
Assess
Crystal Structure of a GDP-bound G12C Oncogenic Mutant of Human GTPase KRasmonomer1-169
GDP;MG;
Assess
X-RAY STRUCTURE OF HUMAN K-RAS G12C IN COMPLEX WITH COVALENT ISOQUINOLINONE INHIBITOR (COMPOUND 17)monomer1-169
GDP;MG;MZN;
Assess
Crystal Structure of GMPPNP-bound KRAS-G13D mutant at 1.2 Ang resolutionmonomer1-169
GNP;MG;
Assess
Crystal structure of KRAS G12D in complex with GDP and compound 14monomer1-169
GDP;MG;VR5;
Assess
KRasG12C in complex with GDP and compound 2monomer1-169
MG;H40;GDP;
Assess
Second-site screening of K-Ras in the presence of covalently attached first-site ligandsmonomer1-169
GDP;MG;2XE;
Assess
Crystal Structure of GDP-bound Human KRasmonomer1-169
GDP;MG;
Assess
Crystal Structure of KRAS G12D with compound 15 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8…monomer1-169
GDP;MG;7L8;
Assess
Crystal structure of KRAS G12D with compound 36 (4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-7-(8…monomer1-169
GDP;7OE;MG;
Assess
KRasG12C ligand complexmonomer1-169
MG;GDP;MKZ;
Assess
Crystal structure of human KRAS in space group R32monomer1-169
MG;GOL;TRS;PEG;GDP;
Assess
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activationmonomer1-169
GDP;MG;0QX;
Assess
Crystal structure of KRAS G12D in complex with GDP and compound 5monomer1-169
GDP;MG;VM9;
Assess
KRasG12C ligand complexmonomer1-169
MG;GDP;O7K;SO4;
Assess
Crystal Structure of small molecule ARS-1620 covalently bound to K-Ras G12Cmonomer1-169
CA;91S;GOL;GDP;
Assess
Second-site screening of K-Ras in the presence of covalently attached first-site ligandsmonomer1-169
GDP;MG;2XO;
Assess
Crystal structure of wild-type KRAS bound to GDP and Mg (Space group C2)monomer1-169
GDP;MG;
Assess
Crystal structure of compound 1 bound to K-Ras(G12D)monomer1-169
GDP;MG;Y63;
Assess
Crystal structure of human KRAS with extended switch I loopmonomer1-169
GDP;MG;CL;
Assess
GDP-bound KRAS P34R mutantmonomer1-169
GDP;MG;
Assess
Crystal Structure of Small Molecule Disulfide 2C07 Bound to K-Ras Cys Light M72C GDPmonomer1-169
MG;GDP;92V;
Assess
Crystal structure of human KRAS G12C covalently bound to a quinazolinone inhibitormonomer1-169
GDP;CA;OHY;
Assess
Crystal structure of human KRAS G12C covalently bound with Araxes WO2020/028706A1 compound I-1monomer1-169
MG;GDP;U4L;
Assess
Crystal structure of KRAS G12D in complex with GDP and compound 8monomer1-169
GDP;MG;VQT;
Assess
Human K-Ras G12D (GDP-bound) in complex with cyclic peptide inhibitor AP10343monomer2-170
GDP;MG;SO4;
Assess
KRAS mutant-A59G in GDP-boundmonomer1-169
MG;GDP;
Assess
Crystal Structure of KRAS G12D with compound 25 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8…monomer1-169
GDP;MG;7NL;GOL;EDO;
Assess
Crystal structure of KRAS-K104Q mutant, GDP-boundmonomer1-169
GDP;MG;SO4;
Assess
Crystal Structure of KRasG13C in Complex with Nucleotide-based Covalent Inhibitor edaGDPmonomer1-169
VJ8;
Assess
Crystal structure of WT KRAS4a with bound GMPPNP and Mg ionmonomer1-169
GNP;MG;
Assess
GDP-bound KRAS G12C in complex with YK-8Smonomer1-169
GDP;MG;DWI;
Assess
Crystal structure of K-Ras(G12D) GppNHp bound to cyclic peptide ligand KD2monomer1-169
GNP;MG;
Assess
Crystal structure of human KRAS G12A mutant in complex with GTPmonomer1-169
GTP;MG;
Assess
X-RAY STRUCTURE OF HUMAN K-RAS G12C IN COMPLEX WITH COVALENT ISOQUINOLINONE INHIBITOR (COMPOUND 3)monomer1-169
GDP;MG;MZQ;
Assess
Crystal Structure of human KRAS G12C covalently bound to AMG 510monomer1-169
MG;GDP;MOV;
Assess
Co-crystal Structure of KRAS (G12C) covalently bound with Quinazoline based inhibitor JBI739monomer1-169
MG;GDP;94F;EDO;
Assess
Crystal structure of human KRAS G12A mutant in complex with GDPmonomer1-169
GDP;MG;PGE;NA;
Assess
Co-crystal Structure of KRAS (G12C) covalently bound with Quinazoline based inhibitor JBI484monomer1-169
MG;GDP;94C;EDO;
Assess
Crystal Structure of KRasG13C in Complex with Nucleotide-based covalent Inhibitor bdaGDPmonomer1-169
VJB;
Assess
Crystal structure of small molecule acrylamide 1 covalently bound to K-Ras G12Cmonomer1-169
GDP;MG;8YD;
Assess
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activationmonomer1-169
GDP;MG;0QV;
Assess
Second-site screening of K-Ras in the presence of covalently attached first-site ligandsmonomer1-169
GDP;MG;2XG;
Assess
Tetrahydropyridopyrimidines as Covalent Inhibitors of KRAS-G12Cmonomer1-169
GDP;MG;K9J;
Assess
Crystal Structure of small molecule alpha,beta-ketoamide 4 covalently bound to K-Ras(G12R)monomer1-169
MG;P7U;GDP;
Assess
Crystal Structure of compound 10 covalently bound to K-Ras G12Cmonomer1-169
GDP;MG;BQD;GOL;
Assess
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activationmonomer1-169
GDP;MG;0QR;
Assess
Crystal structure of human WT-KRAS in complex with GDPmonomer1-169
GDP;MG;
Assess
Crystal structure of human KRAS Q61A mutant in complex with GDPmonomer1-169
GDP;MG;
Assess
KRas G12C in complex with Compound 5cmonomer1-169
GDP;MG;IQC;
Assess
KRas G12C in complex with Compound 7bmonomer1-169
GDP;MG;SO4;IQN;
Assess
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activationmonomer1-169
GDP;MG;0QY;
Assess
Crystal structure of human KRAS G12D mutant in complex with GDPmonomer1-169
GDP;MG;GOL;
Assess
Crystal structure of human KRAS G12A mutant in complex with GTP-gamma-Smonomer1-169
MG;GSP;
Assess
Crystal Structure of a G12C Oncogenic Variant of Human KRas Bound to a Novel GDP Competitive Covale…monomer1-169
MG;Y9Z;
Assess
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the…monomer1-169
GDP;MG;M1X;
Assess
Crystal structure of human KRAS G12A mutant in complex with GppNHpmonomer1-169
MG;9GM;
Assess
Crystal structure of human KRAS A59G mutant in complex with GCPmonomer1-169
GCP;
Assess
Antibody derived (Abd-7) small molecule binding to KRAS.monomer1-169
MG;GNP;D1W;
Assess
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the…monomer1-169
GDP;MG;QH4;
Assess
KRAS G12D in complex with Compound 5B (7-(8-chloronaphthalen-1-yl)-8-fluoro-2-{[(2S)-1-methylpyrrol…monomer1-169
GDP;MG;7IZ;GOL;
Assess
GDP-bound KRAS G12D in complex with YK-8Smonomer1-169
GDP;MG;DNU;
Assess
Structural basis of impaired hydrolysis in KRAS Q61H mutantmonomer1-169
GTP;MG;
Assess
Crystal structure of GDP-bound T50I mutant of human KRAS4Bmonomer1-169
GDP;MG;
Assess
Crystal structure of human KRAS G12A mutant in complex with GDP (EDTA soaked)monomer1-169
MG;GDP;
Assess
The haddock model of GDP KRas in complex with promethazine using NMR chemical shift perturbationsmonomer1-169
GDP;MG;ZM7;
Assess
The haddock model of GDP KRas in complex with promazine using chemical shift perturbations and inte…monomer1-169
GDP;MG;P2Z;
Assess
The HADDOCK structure model of GDP KRas in complex with its allosteric inhibitor E22monomer1-169
GDP;MG;QPD;
Assess
KRAS G12D in complex with MRTX-1133monomer2-169
GDP;6IC;MG;
Assess
Crystal Structure of small molecule ARS-917 covalently bound to K-Ras G12Cmonomer1-168
CA;8ZG;GOL;GDP;
Assess
Crystal structure of wild-type KRAS (1-169) bound to GDP and Mg (Space group P3)monomer1-168
MG;GDP;GOL;
Assess
Crystal Structure of small molecule vinylsulfonamide 15 covalently bound to K-Ras G12Cmonomer1-168
GDP;
Assess
Crystal structure of GMPPNP-bound G12R mutant of human KRAS4bmonomer1-168
MG;GNP;
Assess
Structure of Mg-free KRAS4b (2-169) bound to GDP with the switch-I in fully open conformationmonomer2-169
GDP;
Assess
Crystal structure of human KRAS G12V mutant in complex with GDPmonomer1-168
MG;GDP;
Assess
Crystal structure of KRAS4a-R151G with bound GDP and Mg ionmonomer1-168
GDP;MG;
Assess
Crystal Structure of KRAS G12D with compound 24 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8…monomer2-169
GDP;7NZ;MG;
Assess
KRAS-G13D-GDP in complex with Cpd36 ((E)-1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-…monomer2-169
MG;GDP;XV3;
Assess
Crystal Structure of small molecule vinylsulfonamide covalently bound to K-Ras G12Cmonomer1-168
MG;21R;GDP;
Assess
KRAS full length G12V GPPNHPmonomer2-169
MG;GNP;
Assess
Crystal structure of KRAS V14I-GDP demonstrating disorder switch 1 conformation - Form 2monomer1-168
GDP;
Assess
KRasG12C in complex with GDP and JDQ443monomer1-168
MG;H2T;GDP;
Assess
KRAS G12C IN COMPLEX WITH GDP AND COMPOUND 9monomer1-168
MG;NZX;GDP;
Assess
Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitormonomer1-168
CA;GDP;O5S;
Assess
Discovery of a KRAS G12V Inhibitor in vivo Tool Compound starting from an HSQC-NMR based Fragment H…monomer1-168
2XO;GDP;MG;LX6;
Assess
Crystal Structure of small molecule vinylsulfonamide 14 covalently bound to K-Ras G12Cmonomer1-168
GDP;
Assess
Tetrahydropyridopyrimidines as Covalent Inhibitors of KRAS-G12Cmonomer2-169
GDP;MG;K9M;
Assess
Crystal structure of human KRAS G12C covalently bound with AstraZeneca WO2020/178282A1 compound 76monomer1-168
MG;GDP;U4U;
Assess
Crystal structure of KRAS-G12D/K104Q mutant, GDP-boundmonomer1-168
GDP;MG;
Assess
Crystal Structure of human KRAS G12D mutant in complex with GDPNPmonomer1-168
MG;GNP;
Assess
KRasG12C in complex with GDP and compound 3monomer1-168
MG;H0O;GDP;
Assess
Crystal structure of human WT-KRAS in complex with GTPmonomer1-168
GTP;MG;
Assess
Crystal structure of human WT-KRAS in complex with GTP-gamma-Smonomer1-168
GSP;MG;
Assess
GDP-bound KRAS G12D in complex with TH-Z835monomer1-168
MG;GDP;05I;
Assess
Crystal Structure of small molecule acrylamide 16 covalently bound to K-Ras G12Cmonomer1-168
MG;GDP;
Assess
Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor.monomer1-168
CA;GDP;O67;
Assess
GDP-bound KRAS G12D in complex with TH-Z816monomer1-168
MG;05C;GDP;
Assess
KRAS P34R mutant structure in complex with GTP analoguemonomer1-168
GNP;MG;
Assess
Crystal structure of KRAS G12C in complex with GNE-1952monomer2-169
MKZ;GDP;MG;
Assess
Crystal structure of human KRAS G12C covalently bound with Taiho WO2020/085493A1 compound 6monomer1-168
MG;GDP;U50;SO4;
Assess
GDP-bound KRAS G12D in complex with TH-Z827monomer1-168
MG;GDP;05F;
Assess
Crystal structure of human WT-KRAS in complex with GDP (EDTA soaked)monomer1-168
GDP;MG;
Assess
Crystal structure of wild-type KRAS4b(1-169) in complex with GMPPNP and Mg ionmonomer1-168
GNP;MG;
Assess
Crystal structure of N-acetylated KRAS (2-169) bound to GDP and Mgmonomer2-168
MG;GDP;ACE;
Assess
Crystal Structure of a GDP-bound G13D Oncogenic Mutant of Human GTPase KRasmonomer1-167
GDP;MG;
Assess
KRasG12C ligand complexmonomer1-167
V4T;MG;GDP;CA;
Assess
Crystal Structure of small molecule ARS-107 covalently bound to K-Ras G12Cmonomer1-167
CA;C8G;GDP;
Assess
KRAS G12D Mutant in complex with GMPPCP and cyclic peptide MP-9903monomer1-167
GCP;MG;
Assess
Crystal structure of KRAS-G12D bound to GDP with switch 1 open conformationmonomer2-168
GDP;MG;
Assess
Crystal Structure of small molecule ARS-853 covalently bound to K-Ras G12Cmonomer1-167
MG;GOL;5UT;GLY;GDP;
Assess
Crystal Structure of KRAS-G12D in complex with GMP-PCPmonomer1-167
GCP;MG;
Assess
Crystal Structure of a GDP-bound G12V Oncogenic Mutant of Human GTPase KRasmonomer1-167
GDP;MG;
Assess
CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH 15monomer1-167
GCP;MG;F0N;
Assess
Crystal structure of KRAS V14I-GDP demonstrating open switch 1 conformation - Form 1monomer3-169
GDP;
Assess
Crystal Structure of K-Ras G12C, GDP-boundmonomer1-167
GDP;MG;NA;
Assess
Crystal Structure of small molecule vinylsulfonamide 13 covalently bound to K-Ras G12Cmonomer1-167
GDP;
Assess
KRAS G12C inhibitormonomer1-167
GDP;MG;91G;
Assess
Crystal Structure of small molecule vinylsulfonamide 7 covalently bound to K-Ras G12Cmonomer1-167
GDP;
Assess
Crystal structure of human KRAS G12C covalently bound to a phthalazine inhibitormonomer1-167
MG;GDP;OJ1;
Assess
KRAS-169 Q61H GPPNHP + PPIN-1monomer1-167
GNP;MG;CIT;F6E;
Assess
CRYSTAL STRUCTURE OF KRAS-G12D(C118S) IN COMPLEX WITH BI-2852 AND GDPmonomer1-167
MG;GDP;F0K;SO4;
Assess
CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH BI 2852monomer1-167
F0K;MG;GCP;
Assess
KRAS-169 Q61H GPPNHP + PPIN-2monomer1-167
GNP;MG;CIT;
Assess
KRasG12C ligand complexmonomer1-167
MG;GDP;PQI;
Assess
CRYSTAL STRUCTURE OF KRAS-G12D IN COMPLEX WITH COMPOUND 13 AND GCPmonomer1-167
GCP;MG;
Assess
Crystal structure of GDP-bound KRAS with ten residues long internal tandem duplication in the switc…monomer1-167
GDP;MG;SO4;
Assess
CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH 18monomer1-167
MG;NO3;GCP;EZZ;
Assess
KRAS G12C IN COMPLEX WITH GDP AND COMPOUND 16monomer1-167
MG;NZ6;GDP;
Assess
Antibody derived (Abd-6) small molecule binding to KRAS.monomer1-167
MG;GNP;D1Z;
Assess
Crystal structure of human KRAS P34R mutant in complex with GNP and Phosphatemonomer1-167
GNP;MG;PO4;
Assess
Crystal Structure of small molecule acrylamide 11 covalently bound to K-Ras G12Cmonomer1-167
GDP;
Assess
KRAS G12C in bound to quinazoline based switch II pocket (SWIIP) bindermonomer1-167
GDP;MG;91D;
Assess
Crystal Structure of a GDP-bound Q61L Oncogenic Mutant of Human GT- Pase KRasmonomer1-167
GDP;MG;
Assess
Crystal structure of human KRAS P34R mutant in complex with GNPmonomer1-167
MG;PO4;GNP;
Assess
KRASG12C GDP form in complex with Cpd4monomer1-167
GDP;QY5;
Assess
KRAS-169 Q61H GPPNHP + CH-2monomer1-167
MG;GNP;F8K;
Assess
KRAS G12C in bound to quinazoline based switch II pocket (SWIIP) bindermonomer1-167
GDP;MG;8ZG;
Assess
Human K-Ras (Q61H) in complex with a GTP analoguemonomer1-167
MG;GNP;UNX;
Assess
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the…monomer1-167
GDP;MG;M1R;
Assess
MgGDP bound KRAS G12Vmonomer1-167
MG;GDP;
Assess
KRAS mutant-D33E in GDP-boundmonomer1-167
GDP;MG;
Assess
Antibody derived (Abd-5) small molecule binding to KRAS.monomer1-167
MG;GNP;D2W;
Assess
Covalent GTP-competitive inhibitors of KRAS G12C: Guanosine bisphosphonate Analogsmonomer1-167
6ZD;
Assess
KRAS-169 Q61H GPPNHP + CH-3monomer1-167
MG;GNP;F8Q;
Assess
KRAS-169 Q61H GPPNHP + CH-1monomer1-167
MG;GNP;F8T;
Assess
Second-site screening of K-Ras in the presence of covalently attached first-site ligandsmonomer1-166
GDP;MG;2XH;
Assess
KRAS-G13D-GDP in complex with Cpd38 ((E)-1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-…monomer2-167
GOL;GDP;MG;XQ6;
Assess
Crystal Structure of K-Ras WT, GDP-boundmonomer1-166
GDP;CA;NA;
Assess
CRYSTAL STRUCTURE OF KRAS G12D (GPPCP) IN COMPLEX WITH 22monomer1-166
MG;GCP;F0B;
Assess
KRASG12C GDP form in complex with Cpd3monomer1-166
GDP;MG;PO4;QWK;
Assess
Crystal structure of Mg-free KRAS-G12D bound to GDPmonomer2-167
GDP;
Assess
Wild-type K-Ras(GCP) pH 6.5monomer1-166
GDP;MG;GOL;
Assess
Crystal Structure of small molecule vinylsulfonamide 9 covalently bound to K-Ras G12C, alternative …monomer2-167
MG;21F;GDP;
Assess
KRAS G13D bound to GDP (K13GDP)monomer1-166
GDP;CA;NA;
Assess
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activationmonomer1-166
GDP;MG;0QW;
Assess
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation.monomer1-166
GDP;MG;
Assess
KRAS-G13D-GDP in complex with Cpd5 (1-((S)-10-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-11…monomer2-167
XOI;GDP;CL;MG;
Assess
Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor.monomer2-167
CA;GDP;O5V;
Assess
Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor.monomer1-166
MG;GDP;O5Y;
Assess
KRAS G13D bound to GppNHp (K13GNP)monomer1-166
GNP;MG;
Assess
Crystal structure of Mg-free wild-type KRAS (2-166) bound to GMPPNP in the state 1 conformationmonomer2-166
NA;EDO;GNP;
Assess
Crystal structure of KRas G12V/D38P, bound to GDPmonomer1-165
GDP;
Assess
KRAS-G13D in complex with BI-2493monomer1-164
GDP;MG;EDO;VU6;
Assess
KRAS-G12V in complex with BI-2865monomer1-164
GDP;MG;EDO;OFU;
Assess
KRAS-G12C in complex with BI-2865monomer1-164
GDP;MG;EDO;OFU;
Assess
KRAS-G13D in complex with BI-2865monomer1-164
GDP;MG;EDO;OFU;
Assess
KRAS in complex with BI-2865monomer1-164
GDP;MG;EDO;OFU;
Assess
KRasG12C ligand complexmonomer1-164
MG;GDP;PUO;
Assess
KRAS G12D (GppCp) with MRTX-1133monomer1-164
6IC;GCP;GDP;GOL;ACT;MG;
Assess
KRASG12C GDP form in complex with Cpd1monomer1-164
GDP;MG;QWB;
Assess
KRasG12C ligand complexmonomer1-164
MG;GDP;VLE;
Assess
Crystal structure of oncogenic KRAS Q61E GMPPCP-boundmonomer1-164
GCP;MG;
Assess
KRAS-G12C in Complex with Compound 1monomer1-164
GDP;MG;WYU;
Assess
KRAS in complex with precursor 1monomer1-164
GDP;MG;EDO;LR4;
Assess
CRYSTAL STRUCTURE OF BIT-BLOCKED KRAS-G12V-S39C IN COMPLEX WITH COMPOUND 20amonomer1-164
GDP;2XO;MG;LXU;
Assess
Crystal Structure of K-Ras(G12S)monomer1-164
GDP;MG;
Assess
Crystal Structure of small molecule beta-lactone 5 covalently bound to K-Ras(G12S)monomer1-164
GDP;I7H;MG;
Assess
Crystal Structure of small molecule beta-lactone 1 covalently bound to K-Ras(G12S)monomer1-164
MG;I6T;GDP;SO4;
Assess
KRASG12C GDP form in complex with Cpd2monomer1-164
QWH;GDP;MG;SO4;
Assess
CRYSTAL STRUCTURE OF KRAS-G12C IN COMPLEX WITH COMPOUND 12monomer1-164
GDP;MG;LXK;SO4;
Assess
CRYSTAL STRUCTURE OF KRAS-G12C IN COMPLEX WITH COMPOUND 23 (BI-0474)monomer2-164
GDP;MG;LXD;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
4dso.1.Amonomer0.852-181
88.77
Assess